TY - JOUR T1 - Mediterranean Diet improves thrombosis biomarkers in high cardiovascular risk individuals: a randomized controlled trial JF - medRxiv DO - 10.1101/19001909 SP - 19001909 AU - Álvaro Hernáez AU - Olga Castañer AU - Anna Tresserra-Rimbau AU - Xavier Pintó AU - Montserrat Fitó AU - Rosa Casas AU - Miguel Ángel Martínez-González AU - Dolores Corella AU - Jordi Salas-Salvadó AU - José Lapetra AU - Enrique Gómez-Gracia AU - Fernando Arós AU - Miquel Fiol AU - Lluis Serra-Majem AU - Emilio Ros AU - Ramón Estruch Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/08/22/19001909.abstract N2 - Following a Traditional Mediterranean diet (TMD) decreases cardiovascular risk. However, its anti-thrombotic effects are unexplored. We aimed to assess whether this dietary pattern improved thrombosis-related biomarkers in high cardiovascular risk subjects. In 358 random PREDIMED Study volunteers (Prevención con Dieta Mediterránea), we assessed: 1) 1-year effects of a TMD, enriched in virgin olive oil (TMD-VOO; N=120) or nuts (TMD-Nuts; N=119) versus a low-fat diet (N=119), on thrombosis biomarkers; 2) the differences between individuals with greater TMD compliance increments (≥3 adherence score points) and those with compliance decrements; and 3) associations between 1-year changes in key TMD food groups and thrombosis signals. TMD-VOO and TMD-Nuts attenuated pro-thrombotic status (−5.1% –P=0.045– and −5.8% –P=0.025–, respectively). TMD-VOO decreased HDL-bound α1-antitrypsin levels (HDL pro-inflammatory/pro-thrombotic properties, −6.3%, P=0.034) and increased HDL platelet activating factor-acetylhydrolase activity (+7.5%, P=0.044). TMD-Nuts diminished non-esterified fatty acid levels (−10.3%, P=0.022). Individuals with greater TMD adherence increments presented decreases in their pro-thrombotic status (−9.5%, P=0.032), fibrinogen levels (−9.1%, P=0.030), and non-esterified fatty acid concentrations (−18.1%, P=0.011). Only the low-fat diet was associated with increased platelet factor-4 concentrations (P=0.012) and thrombin activation (higher prothrombin factor1+2 levels, P=0.003) versus baseline. Finally, in the secondary analyses, nut intake increases were associated with antithrombin increments, fruit and vegetable consumption increases were linked to decreases of thrombin activation, and processed meat intake decrements were related to increases in antithrombin and nitrite + nitrate levels (P<0.05). Summarizing, TMD and some of its typical food items were associated with improved thrombosis biomarkers in high cardiovascular risk individuals.KEY POINTSFollowing a Mediterranean diet improves thrombosis-related biomarkers in high cardiovascular risk individualsCompeting Interest StatementX.P. reports personal fees from Abbott, Esteve, Lacer, Rubio, and Sanofi outside the submitted work. J.S.-S. reports to be a board member and grants from Nut and Dried Fruit; personal fees from Aguas Font Vella Lanjarón, Danone S.A., and Instituto Danone; grants from Eroski Distributors; and non-financial support from Nuts for Life outside the submitted work. F.A. reports personal fees from Menarini and AstraZeneca outside the submitted work. E.R. reports personal fees and non-financial support from Merck, Sharp & Dohme; grants, personal fees, and non-financial support from California Walnut Commission; grants and personal fees from Sanofi; personal fees and non-financial support from Ferrer International; and grants from Pfizer outside the submitted work. R.E. reports grants from Bicentury SA, Cerveza y Salud, Grand Fountaine, and Novartis SA; and personal fees from Brewers of Europe, FIVIN, Fundación Cerveza y Salud, Lilly Laboratories, and Wine and Culinary International Forum outside the submitted work. The rest of the authors have nothing to disclose.Clinical TrialISRCTN35739639Funding StatementThis work was supported by grants of Instituto de Salud Carlos III [OBN17PI02, PIE14/00045_INFLAMES, CB06/03/0019, CB06/03/0028, CD17/00122 (A.H.), and JR17/00022 (O.C.)], and Agència de Gestió d'Ajuts Universitaris i de Recerca (2017 SGR 222). The sponsors of this study are public/nonprofit organizations that support science in general and had no role in gathering, analyzing, or interpreting the data. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesConsidering that we do not have the explicit written consent of the study volunteers to yield their deidentified data at the conclusion of the study, individual participant data cannot be shared. The study protocol is available in the main publication of the study1 and in the study website (http://www.predimed.es/uploads/8/0/5/1/8051451/_1estr_protocol_olf.pdf), and a summary of the dietary intervention is also available in Supplemental Methods. ER -